About
About CellaVision AB (publ)
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
Visit company website
5 years, 5 months ago
CellaVision AB (publ) is currently in a long term uptrend where the price is trading 23.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.6.
CellaVision AB (publ)'s total revenue sank by 41.3% to $88M since the same quarter in the previous year.
Its net income has dropped by 45.3% to $13M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.4% to $22M since the same quarter in the previous year.
Based on the above factors, CellaVision AB (publ) gets an overall score of 3/5.